ArticleCancer management and research2026
Inhibition of CDK1 Promotes Immunogenic Cell Death in Neuroblastoma.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroblastoma is characterized by multiple immune evasion strategies, making it critical to explore the use of immunotherapy. CDK1 is known for its role in regulating cell cycle progression and is aberrantly expressed in various tumors, yet its role in NB and immunogenic cell death remains unclear. Methods: We investigated the association between the expression of CDK1 and the outcome of neuroblastoma according to the TCGA database and confirmed the results by tissue arrays. Furthermore, we evaluated the correlation between CDK1 expression and immune cell infiltration as well as cytokine effectiveness. Finally, in vitro and in vivo experiments were used to confirm the effects of a CDK1 inhibitor. Results: CDK1 was overexpressed in advanced neuroblastoma and was associated with poor prognosis. High CDK1 expression correlated with reduced immune cell infiltration and decreased levels of effector cytokines including IL-12, IFN-γ, and IRF1. Furthermore, the inhibition of CDK1 slowed the growth of neuroblastoma cells and promoted immunogenic cell death in neuroblastoma. CDK1 inhibition via RO-3306 suppressed tumor growth and induced hallmark features of ICD, including CRT exposure, HSP70 expression, and HMGB1 release. Conclusion: CDK1 inhibition not only slows neuroblastoma progression but also triggers DAMP release consistent with ICD and immune activation. CDK1 may be a potential prognostic marker and effective treatment target for improving immunotherapy efficacy in neuroblastoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.